Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

The SITC posters will be available on ImCheck's corporate website after the poster sessions have been opened.

Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds ...

CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Present at the 12th Interna ...

CureVac (CVAC) announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...

This approval marks the second international marketing authorization for sugemalimab outside of China, following its ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based o ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global ...

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting ...

TACTI-003 Cohort B: Eftilagimod Alpha (Soluble LAG-3) and Pembrolizumab in First-Line Recurrent or Metastatic Head & Neck ...

Media Release SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a ...